D&O Ongoing and Initial Disclosure Notices

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 4 October 2022
Date of last disclosure: 28 June 2022

Director or senior manager giving disclosure
Full name(s): Brent Pattison
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Chief Executive Officer

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s):
Beneficial interest in shares
issued under the terms of the
Oceania Healthcare Employee
Share Scheme
For that relevant interest -
Number held in class before acquisition or disposal: 1,373
Number held in class after acquisition or disposal: 2,231
Current registered holder(s): New share issue
Registered holder(s) once transfers are registered: OCA Employees Trustee Limited

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A

Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 27 September 2022
Nature of transaction: Acquisition of beneficial interest in
858 ordinary shares in Oceania
Healthcare Limited in accordance
with the Employee Share Scheme
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$799.83
Number of financial products to which the transaction
related:
858
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: Ordinary shares
Nature of relevant interest:
Registered and beneficial owner
of shares
For that relevant interest -
Number held in class: 231,343
Current registered holder(s): Brent Pattison
For a derivative relevant interest -
Type of derivative: N/A

Details of derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 4 October 2022
Name and title of authorised person: Anna Thorburn
Group General Manager
Corporate Services

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 4 October 2022
Date of last disclosure: 28 June 2022

Director or senior manager giving disclosure
Full name(s): Kathryn Waugh
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Chief Financial Officer

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s):
Registered and/or beneficial
ownership of ordinary shares
For that relevant interest -
Number held in class before acquisition or disposal: (1) Beneficial interest in 2,153
ordinary shares issued under the
terms of the Oceania Healthcare
Employee Share Scheme
(2) Registered and beneficial
ownership of 12,270 ordinary
shares
Number held in class after acquisition or disposal:
(1) Beneficial interest in 2,231
ordinary shares issued under the
terms of the Oceania Healthcare
Employee Share Scheme
(2) Registered and beneficial
ownership of 13,050 ordinary
shares
Current registered holder(s): (1) OCA Employees Trustee
Limited
(2) Kathryn Waugh
Registered holder(s) once transfers are registered: As above

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: Two
Details of transactions requiring disclosure -
Date of transaction: (1) 27 September 2022
(2) 3 October 2022
Nature of transaction:
(1) Acquisition of beneficial
interest in 858 ordinary shares in
Oceania Healthcare Limited in
accordance with the Employee
Share Scheme
(2) Vesting of 780 ordinary shares
pursuant to the terms of the
Oceania Healthcare Employee
Share Scheme and transfer of
those vested ordinary shares from
OCA Employees Trustee Limited
to personal name
Name of any other party or parties to the transaction (if
known):
OCA Employees Trustee Limited
The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
(1) $799.83
(2) N/A – vesting and transfer of
vested shares
Number of financial products to which the transaction
related:
(1) 858
(2) 780
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during

any period without written clearance (a closed period)
include the following details -
Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: N/A
Nature of relevant interest: N/A
For that relevant interest -
Number held in class: N/A
Current registered holder(s): N/A
For a derivative relevant interest -
Type of derivative: N/A
Details of derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:
Date of signature:
or

Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 4 October 2022
Name and title of authorised person: Anna Thorburn
Group General Manager
Corporate Services

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 4 October 2022
Date of last disclosure: 28 June 2022

Director or senior manager giving disclosure
Full name(s): Anna Thorburn
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Group General Manager
Corporate Services

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s): Registered and/or beneficial
ownership of ordinary shares
For that relevant interest -
Number held in class before acquisition or disposal: (1) Beneficial interest in 2,153
ordinary shares issued under the
terms of the Oceania Healthcare
Employee Share Scheme
(2) Registered and beneficial
ownership of 223,101 ordinary
shares
Number held in class after acquisition or disposal: (1) Beneficial interest in 2,231
ordinary shares issued under the
terms of the Oceania Healthcare
Employee Share Scheme
(2) Registered and beneficial
ownership of 223,881 ordinary
shares
Current registered holder(s):
(1) OCA Employees Trustee
Limited
(2) Anna Thorburn
Registered holder(s) once transfers are registered: As above

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: Two
Details of transactions requiring disclosure -
Date of transaction: (1) 27 September 2022
(2) 3 October 2022
Nature of transaction:
(1) Acquisition of beneficial
interest in 858 ordinary shares in
Oceania Healthcare Limited in
accordance with the Employee
Share Scheme
(2) Vesting of 780 ordinary shares
pursuant to the terms of the
Oceania Healthcare Employee
Share Scheme and transfer of
those vested ordinary shares from
OCA Employees Trustee Limited
to personal name
Name of any other party or parties to the transaction (if
known):
OCA Employees Trustee Limited
The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
(1) $799.83
(2) N/A – vesting and transfer of
vested shares
Number of financial products to which the transaction
related:
(1) 858
(2) 780
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during

any period without written clearance (a closed period)
include the following details -
Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: N/A
Nature of relevant interest: N/A
For that relevant interest -
Number held in class: N/A
Current registered holder(s): N/A
For a derivative relevant interest -
Type of derivative: N/A
Details of derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature: 4 October 2022
or

Signature of person authorised to sign on behalf of director
or officer:

Date of signature:
Name and title of authorised person:

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 4 October 2022
Date of last disclosure: 10 December 2021

Director or senior manager giving disclosure
Full name(s): Dr Frances Hughes
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Group General Manager Clinical
and Care Services, Clinical
Director

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s): Beneficial interest in shares
issued under the terms of the
Oceania Healthcare Employee
Share Scheme
For that relevant interest -
Number held in class before acquisition or disposal: 1,373
Number held in class after acquisition or disposal: 2,231
Current registered holder(s): New share issue
Registered holder(s) once transfers are registered: OCA Employees Trustee Limited

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A

Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 27 September 2022
Nature of transaction: Acquisition of beneficial interest in
858 ordinary shares in Oceania
Healthcare Limited in accordance
with the Employee Share Scheme
Name of any other party or parties to the transaction (if
known):

The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$799.83
Number of financial products to which the transaction
related:
858
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: N/A
Nature of relevant interest: N/A
For that relevant interest -
Number held in class: N/A
Current registered holder(s): N/A
For a derivative relevant interest -

Type of derivative: N/A
Details of derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 4 October 2022
Name and title of authorised person: Anna Thorburn
Group General Manager
Corporate Services

---

Initial Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(1) and 298(1), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 4 October 2022
Date on which issuer listed or appointment made: 24 January 2022

Director or senior manager giving disclosure
Full name(s): Andrew Buckingham
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Group General Manager Property
& Development

Summary of relevant interest (excluding specified derivatives)
Class of quoted financial product: Ordinary shares
Number held in class: 858
Nature of relevant interest: Beneficial interest in shares
issued under the terms of the
Oceania Healthcare Employee
Share Scheme
Current registered holder: OCA Employees Trustee Limited

Summary of specified derivatives relevant interest (if applicable)
Type of derivative: N/A
Class of underlying financial products: N/A

Details of derivative
The notional value of the derivative (if any) or the notional
amount of underlying products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
N/A

of the derivative is affected by the value of the underlying
financial products:
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 4 October 2022
Name and title of authorised person: Anna Thorburn
Group General Manager
Corporate Services

---

Initial Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(1) and 298(1), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 4 October 2022
Date on which issuer listed or appointment made: 18 July 2022

Director or senior manager giving disclosure
Full name(s): Anita Hawthorne
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Group General Manager Sales &
Service

Summary of relevant interest (excluding specified derivatives)
Class of quoted financial product: Ordinary shares
Number held in class: 858
Nature of relevant interest: Beneficial interest in shares
issued under the terms of the
Oceania Healthcare Employee
Share Scheme
Current registered holder: OCA Employees Trustee Limited

Summary of specified derivatives relevant interest (if applicable)
Type of derivative: N/A
Class of underlying financial products: N/A

Details of derivative
The notional value of the derivative (if any) or the notional
amount of underlying products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
N/A

of the derivative is affected by the value of the underlying
financial products:
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 4 October 2022
Name and title of authorised person: Anna Thorburn
Group General Manager
Corporate Services